New migraine prevention guidelines lower the treatment threshold — here's what that means in practice

For the first time since 2012, the American Academy of Neurology (AAN) and American Headache Society (AHS) have updated their migraine prevention guidelines. Published simultaneously in Neurology and Headache in August 2026, the new guideline lowers the bar for preventive treatment — now recommending it for adults with 4 or more migraine days per month, or for those whose migraines significantly disrupt work or daily life. It also formally incorporates CGRP-targeted therapies, which have been approved since the last update.

Migraine specialist Ann Pakalnis, MD, of The Ohio State University Wexner Medical Center, says the lower threshold will likely drive more referrals to neurology and headache specialists — a welcome shift. But a major friction point remains: many insurers still require patients to fail older medications before approving CGRP therapies, a step therapy process that often lags behind current evidence.

Key Takeaways:

• Preventive treatment is now recommended at ≥4 migraine days/month — a lower bar than before
• Clinicians may need peer-to-peer insurer consultations and letters of medical necessity to access CGRP therapies
• The guideline does not address FDA-approved medical devices for migraine, leaving a notable gap

Why it matters: With millions of Americans living with migraine, earlier intervention could reduce disability and improve quality of life — but only if payer policies catch up to the science.